Patients were excluded if, on the study day, they required hospitalisation for an acute illness. Patients were otherwise eligible if they were outpatients in the community, electively admitted for diagnostic tests or were inpatients for physical rehabilitation. Age, sex, weight, height, dabigatran etexilate dose rates, co-prescribed medications and comorbidities were recorded. Using these data, we calculated each individual’s CHA2DS2-VASc (1 point for each of Congestive heart failure, Hypertension, Diabetes mellitus, Vascular disease, Age 65–74 years, Female sex, 2 points for each of Age ≥75 years, Previous stroke) and HAS-BLED

(1 point for each of Hypertension, Abnormal renal/liver function, Stroke, Bleeding history or predisposition, Labile international normalized ratio, Elderly, Drugs/alcohol concomitantly) scores, which estimate thromboembolic and haemorrhagic risks, respectively

P5091 cell line [33, 34]. GFR was estimated for each individual using the four equations listed in Table 2. The results from the various CKD-EPI equations were converted from units of mL/min per 1.73 m2 to mL/min according to Eq. 1: $$ \textGFR_\textmL/min = \textGFR_\textmL/min\,per 1.73\,\textm^2 \times \frac\textBSA1.73\,\textm^2 $$ (1)where the body surface area of the individual (BSA) was calculated using Mosteller’s equation [35–39]. 2.3 Sample Collection and Laboratory Analysis Each patient provided a set of venous blood samples 10–16 hours post-dose for SCH727965 in vivo measuring plasma creatinine and cystatin

C concentrations, plasma free thyroxine and thyroid-stimulating hormone (TSH) concentrations (BD Vacutainer® lithium heparin tubes); Pictilisib Hemoclot® Thrombin Inhibitor times (HTI, Hyphen BioMed, Neuville-sur-Oise, France) (BD Vacutainer® citrate tubes); plasma dabigatran concentrations (BD Vacutainer® K2 ethylene diamine tetraacetic acid [EDTA] tubes). Blood cells from the EDTA tubes were used for genotyping. Serum creatinine and cystatin C concentrations were only measured Hydroxychloroquine price at a single point in time for each participant, as intra-individual variance (coefficient of variation, CV) of these biomarker concentrations has been reported to be around 7 % in clinically stable individuals [40]. Serum creatinine was measured using an Abbott® Aeroset analyser (Abbott Park, IL, USA) by the modified Jaffe reaction. This was IDMS-aligned for the period of this study and had an inter-day CV of <4.0 %. Serum cystatin C was measured using a particle-enhanced nephelometric immunoassay on a Behring Nephelometer II analyser (Siemens Diagnostics, Marburg, Germany), with a CV <4.5 % [41]. The use of a contemporary Siemens assay for cystatin C is consistent with the recommendations by Shlipak et al. [42].